<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14888">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812408</url>
  </required_header>
  <id_info>
    <org_study_id>TRX109011</org_study_id>
    <nct_id>NCT01812408</nct_id>
  </id_info>
  <brief_title>TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Migraine Pain, 1 of 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study TRX109011, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover
      Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus
      Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when
      administered during the Moderate-Severe Pain Phase of the Migraine (Study 1 of 2)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, double-blind, double-dummy, placebo-controlled,
      crossover, three-attack, outpatient study in which TREXIMET® will be compared to a
      butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and
      butalbital 50mg [Fioricet]) for the acute treatment of migraine headaches. Subjects will be
      randomized to one of 6 possible treatment sequences (TPB, TBP, BTP, BPT, PTB, PBT where T =
      TREXIMET®; P = Placebo; B = Butalbital-containing Combination Medication) .  Subjects will
      treat each of the 3 migraine attacks when pain is moderate to severe.  The study will
      include 4 visits:  (1) a Screening visit at study entry, (2) a Drug Screen visit, (3) a
      Randomization visit, and (4) a Final visit.  The Final visit occurs either (A) upon
      withdrawal or (B) after treatment of 3 migraine attacks.  The primary objective is to
      evaluate the efficacy of TREXIMET® versus BCM for the acute treatment of moderate/severe
      migraine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained pain-free (SPF) response from 2-24 hours in subjects using TREXIMET® versus those using BCM.</measure>
    <time_frame>2-24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive efficiency as measured by the Mental Efficiency Workload Test (MEWT)</measure>
    <time_frame>0-48 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-free (PF) at 2 hours post-treatment</measure>
    <time_frame>2 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication usage after treatment of migraine</measure>
    <time_frame>0-48 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and traditional and non-traditional associated migraine symptoms including nausea, vomiting, photophobia, phonophobia, sinus pain, neck pain, irritability and tiredness</measure>
    <time_frame>0-48 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>TPB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TREXIMET®</intervention_name>
    <description>Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)</description>
    <arm_group_label>PBT</arm_group_label>
    <arm_group_label>PTB</arm_group_label>
    <arm_group_label>BTP</arm_group_label>
    <arm_group_label>TPB</arm_group_label>
    <arm_group_label>TBP</arm_group_label>
    <arm_group_label>BPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butalbital-containing Combination Medications (BCM)</intervention_name>
    <description>butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]</description>
    <arm_group_label>PBT</arm_group_label>
    <arm_group_label>PTB</arm_group_label>
    <arm_group_label>BTP</arm_group_label>
    <arm_group_label>TPB</arm_group_label>
    <arm_group_label>TBP</arm_group_label>
    <arm_group_label>BPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>PBT</arm_group_label>
    <arm_group_label>PTB</arm_group_label>
    <arm_group_label>BTP</arm_group_label>
    <arm_group_label>TPB</arm_group_label>
    <arm_group_label>TBP</arm_group_label>
    <arm_group_label>BPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18 to 65 years.  Female subjects are eligible for
             participation if they are either of non-childbearing potential (not capable of
             becoming pregnant) OR of childbearing potential having a negative urine pregnancy
             test at screening, and using contraception if sexually active.  If using oral
             contraceptives, the subjects should be on a stable regimen of oral contraceptives
             (&gt;/= 2 months).

        Eligible subjects must:

          -  have migraine with or without aura (2004 ICHD-II criteria) and must have had at least
             2 attacks per month meeting these criteria in the three months prior to screening.

          -  have documented use of Butalbital-containing Combination Medication (MCM) to have
             treated at least one migraine.

          -  be able to understand how to complete the cognitive assessments and all other
             questionnaires programmed in an electronic diary.

          -  be willing and able to provide written informed consent.

        Exclusion Criteria:

        A subject is not eligible if they have:

          -  &gt;8 migraines or &gt;/= 15 headache days per month in total, or has retinal, basilar, or
             hemiplegic migraine, or secondary headaches.

          -  taken &gt;350mg/day of butalbital and/or other barbiturates on an equivalent dose basis,
             on average, over the 30 days prior to screening.

          -  is likely to have unrecognized cardiovascular or cerebrovascular disease (based on
             history or risk factors).

          -  blood pressure &gt;/= 140/90mmHg in 2 out of 3 BP measurements or is taking any
             angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.

          -  history of congenital heart disease, cardiac arrhythmias requiring medication, or a
             clinical significant electrocardiogram abnormality.

          -  evidence or history of any ischemic vascular disease including:  ischemic heart
             disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's
             Syndrome, or signs/symptoms consistent with these.

          -  evidence or history of central nervous system pathology including stroke and/or
             transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower
             the convulsive threshold; or has been treated with an antiepileptic drug for seizure
             control within 5 years prior to screening.

          -  a history of impaired hepatic or renal function that contraindicates participation in
             the study.

          -  hypersensitivity, allergy, intolerance, or contraindication to the use of any
             triptan, NSAID, aspirin, barbiturates, or acetaminophen (including all sumatriptan
             and naproxen preparations), has porphyria or has nasal polyps and asthma.

          -  is currently taking, or has taken in the previous three months, an ergot preparation
             for migraine prophylaxis; or is taking a migraine or prophylactic medication that is
             not stabilized (i.e. a change of dose within the last 2 months)  for either chronic
             or intermittent migraine prophylaxis or for a co-morbid condition that is not
             stabilized.

          -  a recent history of regular use of opioids (including opioids in combination with
             butalbital, e.g. Fioricet with codeine) or barbiturates other than butalbital.
             Regular use is defined as an average of 4 days per month over the last 6 months.

          -  taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal
             preparations containing St. John's Wort (Hypericum perforatum), anytime within the 2
             weeks prior to screening through 2 weeks post final study treatment.

          -  history of any bleeding disorder or is currently taking any anti-coagulant or any
             antiplatelet agent (except low-dose aspirin &lt;/= 325mg/day for cardioprotective
             reasons).

          -  evidence or history of any gastrointestinal surgery or GI ulceration or perforation
             in the past six months, gastrointestinal bleeding in the past year; or evidence or
             history of inflammatory bowel disease.

          -  is pregnant, actively trying to become pregnant, breast feeding, or not willing to
             have pregnancy test performed.

          -  evidence of alcohol or substance abuse within the last year or any concurrent medical
             or psychiatric condition which, in the investigator's judgement, will likely
             interfere with the study conduct, subject cooperation, or evaluation and
             interpretation of the study results, or which otherwise contraindicates participation
             in this clinical study.

          -  participated in an investigational drug trial within the previous four weeks or plans
             to participate in another study at any time during this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407-2450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>7450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <zip>08084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valley Stream</city>
        <state>New York</state>
        <zip>11580</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614-5809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache. 2001 Nov-Dec;41(10):953-67. Review.</citation>
    <PMID>11903523</PMID>
  </reference>
  <reference>
    <citation>Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia. 2004 Jun;24(6):483-90.</citation>
    <PMID>15154858</PMID>
  </reference>
  <reference>
    <citation>Wenzel RG, Sarvis CA. Do butalbital-containing products have a role in the management of migraine? Pharmacotherapy. 2002 Aug;22(8):1029-35. Review.</citation>
    <PMID>12173787</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine, acute</keyword>
  <keyword>Migraine</keyword>
  <keyword>Butalbital-containing Combination Medication (BCM)</keyword>
  <keyword>Naproxen sodium</keyword>
  <keyword>Sumatriptan succinate</keyword>
  <keyword>TREXIMET®</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
